- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Pant on the Role of Genetic Testing in Pancreatic Cancer
Shubham Pant, MD, discusses the role of genetic testing in pancreatic cancer.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of genetic testing in pancreatic cancer.
Genetic testing has been a welcome addition to the pancreatic cancer armamentarium, says Pant.
Germline genetic testing can identify key inherited mutations within a patient’s blood, explains Pant. Conversely, somatic genetic testing identifies aberrations within the tumor.
Germline and somatic testing results can inform whether a patient is a candidate for targeted therapy, Pant says.
Currently, the National Comprehensive Cancer Network and the ASCO guidelines recommend that all patients with pancreatic cancer undergo germline testing to identify BRCA1/2 mutations, concludes Pant.
Related Content:
